DUBLIN--(BUSINESS WIRE)--The "North America Companion Diagnostics Devices Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
North America Companion Diagnostics Devices market is expected to witness a CAGR of 18.5% during the forecast period.
Certain factors that are driving the market growth include rising demand and awareness for personalized medicine and targeted therapy, increasing cases of adverse drug reactions, technological demands.
The United States takes an exceptional approach to regulate innovative companion diagnostic devices. The US Food and Drug Administration (FDA) approved diagnostic assays play an ever more common role in managing patients to extend lifespan while also enhancing the quality of life. Diagnostic assays have been found to be essential for the safe and effective use of therapeutics (companion diagnostic).
In-situ Hybridization (ISH) Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period
In-situ hybridization (ISH), especially fluorescence in-situ hybridization (FISH), is a reliable, reproducible, sensitive, and accurate procedure, which is less affected by tissue fixation and analytical variables, in comparison to immunochemistry and other techniques. It offers the benefit of simultaneous evaluation of morphology and gene amplification.
FISH has been the method of choice for use in companion diagnostics for several cancer therapies, such as trastuzumab, lapatinib, and criotinib, which have been already approved by FDA and other therapies, like everolimus, ridaforolimus, bicatulamide, TBD, and other drugs, that are yet to obtain regulatory approval.
The North America Companion Diagnostics Devices market is highly competitive and consists of a few major players. Companies like Abbott, Agilent Technologies Inc., Biomerieux SA, Danaher Corporation (Beckman Coulter Inc.), F. Hoffmann-La Roche Ltd, Qiagen NV, Siemens Healthcare, Thermo Fisher Scientific Inc., among others, hold the substantial market share in the Companion Diagnostics Devices market.
Key Topics Covered
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Demand & Awareness for Personalized Medicine & Targeted Therapy
4.2.2 Increasing Cases of Adverse Drug Reactions
4.2.3 Technological Demands
4.3 Market Restraints
4.3.1 High Cost of Drug Development & Associated Clinical Trials
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1.1 Immunohistochemistry (IHC)
5.1.2 Polymerase Chain Reaction (PCR)
5.1.3 In-situ Hybridization (ISH)
5.1.4 Real-time PCR (RT-PCR)
5.1.5 Gene Sequencing
5.1.6 Other Technologies
5.2.1 Lung Cancer
5.2.2 Breast Cancer
5.2.3 Colorectal Cancer
5.2.6 Other Indications
5.3.1 North America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.2 Agilent Technologies Inc.
6.1.3 bioMerieux S.A.
6.1.4 Danaher Corporation (Beckman Coulter Inc.)
6.1.5 F. Hoffmann-La Roche Ltd.
6.1.6 Qiagen N.V.
6.1.7 Siemens Healthcare
6.1.8 Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/s1ebpu